Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Alzheimer's disease
Alzheimer's disease
AbbVie inks $54M settlement to resolve Namenda 'pay-for-delay' lawsuit
Fierce Pharma
Tue, 11/15/22 - 06:37 pm
legal
AbbVie
Namenda
Alzheimer's disease
pay-for-delay
Allergan
Trial failures end latest hope for Roche’s Alzheimer’s drug
BioPharma Dive
Mon, 11/14/22 - 10:57 am
Roche
Alzheimer's disease
gantenerumab
clinical trials
Cassava Files Defamation Suit against Short Sellers Linked to Data Manipulation Allegations - Updated
BioSpace
Fri, 11/4/22 - 10:16 am
Cassava Biosciences
legal
data manipulation
short sellers
simufilam
Alzheimer's disease
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
Motley Fool
Wed, 11/2/22 - 10:51 pm
Denali Therapeutics
clinical trials
Alzheimer's disease
TAK-594
Lilly powers through final stretch in critical Alzheimer's race
Fierce Biotech
Tue, 11/1/22 - 07:02 pm
Eli Lilly
Alzheimer's disease
donanemab
lecanemab
Eisai
Eisai's Alzheimer's hopeful lecanemab may have contributed to patient death: report
Fierce Biotech
Mon, 10/31/22 - 10:30 am
Eisai
patient death
lecanemab
Alzheimer's disease
clinical trials
Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates
Endpoints
Tue, 10/25/22 - 11:05 am
Biogen
earnings
Alzheimer's disease
ALS
tofersen
lecanemab
Where Will Biogen Be in 5 Years?
Motley Fool
Thu, 10/20/22 - 10:39 am
Biogen
Aduhelm
lecanemab
Alzheimer's disease
M&A
Roche CEO Cautious on Alzheimer’s Trial Despite Eisai’s Success
Bloomberg
Wed, 10/19/22 - 10:35 am
Roche
Pharma CEOs
Severin Schwan
Alzheimer's disease
Eisai
gantenerumab
lecanemab
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
Wed, 10/12/22 - 11:03 am
FDA
Biogen
Eisai
Alzheimer's disease
Gilead Sciences
HIV
Mirati Therapeutics
lung cancer
lecanemab
lenacapavir
adagrasib
TauRx’s HMTM could be the first anti-tau disease-modifying drug for Alzheimer’s
Clinical Trials Arena
Tue, 10/11/22 - 04:17 pm
Alzheimer's disease
TauRx
clinical trials
HMTM
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Lecanemab can; now the wait for details begins
EP Vantage
Wed, 09/28/22 - 11:45 am
Biogen
Eisai
lecanemab
clinical trials
Alzheimer's disease
A Biotech Breakthrough Means Big Gains for These 2 Stocks
Motley Fool
Wed, 09/28/22 - 11:02 am
Eli Lilly
Biogen
Alzheimer's disease
lecanemab
donanemab
Biogen/Eisai Alzheimer’s treatment slowed cognitive decline in closely watched clinical trial
Stat
Wed, 09/28/22 - 12:04 am
Biogen
Eisai
Alzheimer's disease
clinical trials
lecanemab
With Lilly's Mounjaro set for stardom, an Alzheimer's win would be 'icing on the cake': analysts
Fierce Pharma
Fri, 09/23/22 - 10:48 am
Eli Lilly
type 2 diabetes
obesity
donanemab
Mounjaro
Alzheimer's disease
AlzeCure’s drug for Alzheimer’s shows positive effect in Phase I trial
Clinical Trials Arena
Mon, 09/19/22 - 09:11 am
AlzeCure
clinical trials
Alzheimer's disease
ACD856
BioVie Biomarker Study Points to Improvements in Alzheimer's
BioSpace
Thu, 09/8/22 - 10:42 am
BioVie
biomarkers
Alzheimer's disease
NE3107
Beyond headlines and amyloid, the Alzheimer's pipeline chugs along
Fierce Biotech
Fri, 09/2/22 - 12:59 pm
Alzheimer's disease
clinical trials
drug development
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity
Fierce Pharma
Mon, 08/29/22 - 10:40 am
Novo Nordisk
semaglutide
NASH
Alzheimer's disease
Saxenda
obesity
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »